BIONTECH SE (BNTX): Price and Financial Metrics


Today's Latest Price: $104.96 USD

3.09 (3.03%)

Updated Nov 25 4:00pm

Add BNTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

BNTX Stock Summary

  • BNTX's went public 1.13 years ago, making it older than only 0.83% of listed US stocks we're tracking.
  • With a price/sales ratio of 200.18, BioNTech SE has a higher such ratio than 98.13% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, BioNTech SE is reporting a growth rate of 292.66%; that's higher than 95.1% of US stocks.
  • Stocks that are quantitatively similar to BNTX, based on their financial statements, market capitalization, and price volatility, are BGNE, MRNA, INCY, ARGX, and DNLI.
  • Visit BNTX's SEC page to see the company's official filings. To visit the company's web site, go to

BNTX Stock Price Chart Interactive Chart >

Price chart for BNTX

BNTX Price/Volume Stats

Current price $104.96 52-week high $115.00
Prev. close $101.87 52-week low $20.49
Day low $99.10 Volume 3,007,400
Day high $106.06 Avg. volume 2,153,023
50-day MA $86.45 Dividend yield N/A
200-day MA $63.95 Market Cap 23.75B


BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders.

BNTX Latest News Stream

Event/Time News Detail
Loading, please wait...

BNTX Latest Social Stream

Loading social stream, please wait...

View Full BNTX Social Stream

Latest BNTX News From Around the Web

Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.

Moderna, Pfizer & BioNTech, and AstraZeneca and the University of Oxford's COVID-19 Vaccine Trials are Entering the Final Stage of Development

DUBLIN, Oct. 2, 2020 /PRNewswire/ -- published a new article on the vaccine industry "COVID-19 Vaccine Trials are Entering the Final Stage of Development" Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the…

PR Newswire | October 2, 2020

COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 Featuring Major Players - Pfizer, GSK, Inovio Pharma, J&J, Novavax, Heat Biologics, Sanofi, BioNTech, Vaxart, and Vir Biotechnology -

DUBLIN--(BUSINESS WIRE)--The "COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020" report has been added to's offering. COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 provides the strategists, marketers and senior management with the critical information they need to assess the global COVID-19 vaccine & therapeutics clinical trial analysis 2020 market. Major players in the COVID-19 vaccine and therapeutics clinical trial analysis market

Business Wire | September 30, 2020

Dr. Fauci just said something surprising about coronavirus vaccines and face masks

Several coronavirus vaccine trials will soon be finished and some of the frontrunners might be deemed safe and effective for emergency use. Health officials from the World Health Organization and Dr. Anthony Fauci warn that the arrival of COVID-19 vaccines won't be enough to reduce the transmission of the illness anytime soon. Fauci says that precautionary measures including face masks, social distancing, and frequent handwashing will need to continue even after vaccines arrive. The FDA will host a significant coronavirus vaccine meeting in just a few weeks, at which point we might find out more details about the progress of experimental drugs that have reached the final phase of testing. Vaccine candidates from AstraZeneca/Oxford, Pfizer/BioNTech, and Moderna have Phase 3 trials underw...

BGR | September 27, 2020

COVID-19 vaccine credibility collapsing - MacroBusiness

It’s not the fruitloop anti-vaxxers fault, either. It’s governments. Via Bloomberg: The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals. The companies plan a first look after a mere 32 coronavirus infections have accumulated in their massive

Macro Business | September 22, 2020

Experts Worry As Leading COVID-19 Vaccines Adopt Trial Shortcuts In "Rush For Results"

Experts Worry As Leading COVID-19 Vaccines Adopt Trial Shortcuts In "Rush For Results" Tyler Durden Tue, 09/22/2020 - 13:05 As doubts about the FDA's credibility grow as the agency awaits the initial results from the frontrunner's "Phase 3" trials, the leading vaccine makers are working to further expedite the approval process by streamlining procedures to try and make a determination about whether their vaccine "works or not" within the next month or so. The issue, as Bloomberg reports , is that the leading vaccine companies are shooting for low targets for the number of confirmed infections among the tens of thousands of patients they've recruited for their trials. Remember, half of the test subjects have been given a vaccine, while the other half haven't. Leading candidates will repo...

Zero Hedge | September 22, 2020

Read More 'BNTX' Stories Here

BNTX Price Returns

1-mo 26.56%
3-mo 60.02%
6-mo 111.91%
1-year 391.39%
3-year N/A
5-year N/A
YTD 209.80%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7583 seconds.